Akums Drugs and Pharmaceuticals share news and announcements
NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹680.20.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹10,530 Cr630th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 8 Aug 2026
- 36.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 3.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.45%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 8 Aug 2026
- 9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 8 Aug 2026
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,89,38152.3% delivered
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Akums Drugs and Pharmaceuticals quarterly results
The board met on 8 Aug 2026 to consider financial results
Notice filed 5 Aug 2026
Akums Drugs and Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Akums Drugs and Pharmaceuticals financials, year by year
Annual reports2
Investor presentations9
- Presentation (opens in a new tab)8 Aug 2026
- Investor Presentation (opens in a new tab)14 May 2026
- Investor Presentation (opens in a new tab)13 Feb 2026
- Investor Presentation (opens in a new tab)13 Nov 2025
- Presentation (opens in a new tab)8 Aug 2025
4 earlier presentations
- Investor Presentation (opens in a new tab)26 May 2025
- Investor Presentation (opens in a new tab)6 Feb 2025
- Investor Presentation (opens in a new tab)9 Nov 2024
- Investor Presentation (opens in a new tab)24 Aug 2024
Earnings calls19
- Transcript (opens in a new tab)13 Aug 2026
- Link of Recording (opens in a new tab)10 Aug 2026
- Transcript of Investors/Analysts Conference Call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-26 (opens in a new tab)21 May 2026
- Link of Audio Recording of Investor/Analysts Conference Call (opens in a new tab)18 May 2026
- Transcript (opens in a new tab)19 Feb 2026
14 earlier call documents
- Transcript (opens in a new tab)19 Feb 2026
- Link of Recording (opens in a new tab)16 Feb 2026
- Transcript (opens in a new tab)17 Nov 2025
- Link of Recording (opens in a new tab)14 Nov 2025
- Transcript (opens in a new tab)18 Aug 2025
- Link of Recording (opens in a new tab)11 Aug 2025
- Transcript (opens in a new tab)2 Jun 2025
- Link of Recording (opens in a new tab)27 May 2025
- Transcript (opens in a new tab)11 Feb 2025
- Link of recordings (opens in a new tab)7 Feb 2025
- Transcript (opens in a new tab)15 Nov 2024
- Link of Recording (opens in a new tab)11 Nov 2024
- Transcript (opens in a new tab)4 Sep 2024
- Link of Recording (opens in a new tab)30 Aug 2024
Akums Drugs and Pharmaceuticals share news and announcements
151 announcements, routine notices left out, newest first. Page 1 of 4.
Oct 2026
15 Oct · Legal
Sep 2026
23 Sep · Analysts
16 Sep · Analysts
3 Sep · General Updates
Aug 2026
25 Aug · Analysts
13 Aug · Analysts
10 Aug · Analysts
5 Aug · Analysts
5 Aug · Board meeting
Jul 2026
Jun 2026
9 Jun · Analysts
May 2026
28 May · Analysts
18 May · Disruption of Operations
16 May · Disruption of Operations
12 May · Analysts
8 May · General Updates
Apr 2026
11 Apr · Rating
Feb 2026
26 Feb · Analysts
13 Feb · Analysts
13 Feb · Business
13 Feb · Board meeting
Jan 2026
31 Jan · Analysts
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts).
- 13 Apr 2026Credit ratingup 1.64%+2.4 pts vs Nifty 500market median 0.0% · five sessions +3.4% (+1.0 pts vs Nifty 500) · volume 2.1× usual · delivery −4.7 pts against usual · The announcement (opens in a new tab)
- 14 Nov 2025Resultsdown 3.00%−3.1 pts vs Nifty 500market median −0.7% · five sessions −3.6% (−4.3 pts vs Nifty 500) · volume 6.1× usual · delivery +2.3 pts against usual · The announcement (opens in a new tab)
- 11 Aug 2025Resultsdown 0.15%−1.0 pts vs Nifty 500market median −0.7% · five sessions −1.2% (−3.4 pts vs Nifty 500) · volume 3.3× usual · delivery −36.6 pts against usual · The announcement (opens in a new tab)
- 27 May 2025Resultsdown 0.78%−0.4 pts vs Nifty 500market median −0.7% · five sessions −2.3% (−2.0 pts vs Nifty 500) · volume 7.4× usual · delivery −19.2 pts against usual · The announcement (opens in a new tab)
- 7 Feb 2025Resultsdown 2.35%−2.2 pts vs Nifty 500market median −0.7% · five sessions −4.2% (−0.6 pts vs Nifty 500) · volume 0.9× usual · delivery −5.0 pts against usual · The announcement (opens in a new tab)
- 11 Nov 2024Resultsdown 10.00%−9.8 pts vs Nifty 500market median −0.7% · five sessions −30.5% (−27.2 pts vs Nifty 500) · volume 2.8× usual · delivery +11.4 pts against usual · The announcement (opens in a new tab)
- 10 Oct 2024Credit ratingup 0.28%+0.3 pts vs Nifty 500market median 0.0% · five sessions +8.1% (+7.8 pts vs Nifty 500) · volume 0.8× usual · delivery −21.5 pts against usual · The announcement (opens in a new tab)
- 26 Aug 2024Resultsdown 5.00%−5.6 pts vs Nifty 500market median −0.7% · five sessions −8.1% (−9.5 pts vs Nifty 500) · delivery +5.0 pts against usual · The announcement (opens in a new tab)
Akums Drugs and Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.